NEO — NeoGenomics, Inc.

NeoGenomics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $186.7 million, an 11% increase year-over-year, exceeding guidance.
• Clinical Revenue: $171 million, up 14% year-over-year, driven by volume growth (6%) and average unit price (AUP) growth (8%).
• Adjusted EBITDA: $9 million, a 27% increase from Q1 2025, with an adjusted EBITDA margin improvement of 60 basis points.
• Nonclinical Revenue: $15.5 million, down 15% year-over-year, primarily due to expected softness in the pharma sector.
• Cash Position: Ended the quarter with $146 million in cash, with cash used in operations reduced to $8.1 million from $25.3 million in the prior year.

2. Strategic Updates and Business Highlights

• Product Launches: Reentry into the minimal residual disease (MRD) market with the RaDaR ST assay, targeting a $20 billion market opportunity. Early customer adoption is promising, with 29% of previous RaDaR users ordering the new test.
• NGS Growth: The next-generation sequencing (NGS) business grew 26%, now comprising about one-third of total clinical revenue. The company is focusing on expanding its NGS portfolio, including the PanTracer liquid biopsy.
• Sales Force Expansion: Plans to add approximately 25 sales resources by Q3 2026 to support new product launches and market penetration.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Increased to $797 million to $803 million, up from previous guidance of $793 million to $801 million, reflecting strong Q1 performance and early MolDX approval for PanTracer Liquid.
• Quarterly Growth Expectations: Anticipated 9% year-over-year growth in Q2, followed by 9% to 10% in Q3, and above 10% in Q4.
• Adjusted EBITDA Guidance: Maintained at $55 million to $57 million for the year, representing a growth of approximately 27% to 31%.

4. Bad News, Challenges, or Points of Concern

• Nonclinical Revenue Decline: The nonclinical business is expected to decline in the low to mid-single digits for the year, with concerns about softness in the pharma sector.
• Gross Margin Pressures: Adjusted gross margin was 46%, down 80 basis points year-over-year, impacted by the Pathline acquisition and higher operational costs due to geopolitical factors.
• High-Volume, Low-Value Contracts: The strategic exit from these contracts is expected to impact volumes in the short term, although it aligns with the company's long-term strategy.

5. Notable Q&A Insights

• NGS Sustainability: Management expressed confidence in sustaining NGS growth rates, driven by the introduction of PanTracer Liquid and ongoing commercial initiatives.
• Market Penetration: The company is optimistic about capturing additional market share in the community oncology setting, where most patients receive treatment.
• Payer Mix: Current liquid biopsy orders are approximately 40% Medicare and 50% commercial, with expectations for improved reimbursement rates as more contracts are established.
• Sales Force Impact: The expansion of the sales force is seen as a critical driver for future growth, particularly in the NGS and MRD segments.

Overall, NeoGenomics reported strong financial performance in Q1 2026, with promising growth in its clinical and NGS segments, while also facing challenges in its nonclinical business and gross margins. The company is strategically positioned for future growth with new product launches and an expanded sales force.